1. Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).
- Author
-
Janzic, Urska, Maimon Rabinovich, Natalie, Shalata, Walid, Kian, Waleed, Szymczak, Katarzyna, Dziadziuszko, Rafal, Jakopovic, Marko, Mountzios, Giannis, Pluzanski, Adam, Araujo, Antonio, Charpidou, Andriani, Daher, Sameh, and Agbarya, Abed
- Subjects
NON-small-cell lung carcinoma ,PROGRESSION-free survival ,PROTEIN-tyrosine kinase inhibitors ,CENTRAL nervous system ,ANTINEOPLASTIC agents - Abstract
ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC patients, diagnosed with advanced metastatic disease, were included. Molecular profiling using either FISH/CISH or NGS was performed on tissue samples. Twenty-eight patients were treated with crizotinib, while fourteen patients were administered newer drugs (entrectinib, repotrectinib) and seven patients received platinum-doublet chemotherapy in a first-line setting. Overall response rate and disease control rate for the crizotinib and entrectinb/repotrectinib cohort were 68% and 82% vs. 86% and 93%, respectively. Median progression free survival was 1.6 years (95% CI 1.15–2.215) for the crizotinib treatment vs. 2.35 years for the entrectinib/repotrectinib cohort (95% CI 1.19–3.52). Central nervous system progression was noted in 20% and 25% of the crizotinib and entrectinib/repotrectinib cohorts, respectively. This multi-center study presents real-world treatment patterns of ROS1 NSCLC population, indicating that crizotinib exhibited comparable results to entrectinib/repotrectinib in a first-line setting, although both response rate and survival was numerically longer with treatment with newer agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF